Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.
Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.
Solid Biosciences is a life science company focused on solving Duchenne muscular dystrophy. We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted by Duchenne muscular dystrophy, our mandate is simple yet comprehensive – attack the roots of the disease and improve daily life for patients.